-Mark J Federspiel Researcher Activity Profile

Research Author Detailed Information 

Mark J Federspiel Publication Rate By Year

Mark J Federspiel has published 4 paper(s) in 2006, 2 paper(s) in 2007, 3 paper(s) in 2008, for a total of 9 research publications in total.

Mark J Mj Federspiel Author Information

LAST NAME: federspiel

FIRST NAME: Mark J

INITIALS: mj

AFFILIATION:

Papers

Mark J Federspiel's Publication Record

1. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Year Published: 2006
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
2. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Year Published: 2006
Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA.
3. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Year Published: 2006
1Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.
4. Recombinant adeno-associated virus vector for gene transfer to the transplanted rat heart. Year Published: 2007
William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN 55905, USA.
5. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. Year Published: 2007
William J. von Liebig Transplant Center, Department of Surgery, Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.
6. A single-amino-acid substitution in the TvbS1 receptor results in decreased susceptibility to infection by avian sarcoma and leukosis virus subgroups B and D and resistance to infection by subgroup E in vitro and in vivo. Year Published: 2008
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídenská 1083, CZ-14220 Prague 4, Czech Republic.
7. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Year Published: 2006
Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA.
8. A single-amino-acid substitution in the TvbS1 receptor results in decreased susceptibility to infection by avian sarcoma and leukosis virus subgroups B and D and resistance to infection by subgroup E in vitro and in vivo. Year Published: 2008
9. Cysteines flanking the internal fusion peptide are required for the avian sarcoma/leukosis virus glycoprotein to mediate the lipid mixing stage of fusion with high efficiency. Year Published: 2008
Department of Cell Biology, UVA Health System, School of Medicine, P.O. Box 800732, Charlottesville, VA 22908-0732, USA. sed7a@virginia.edu